This article is more than 5 years old. Information may no longer be current.

Endothelial cell counts decrease following phakic IOL implantation

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

GUADALAJARA, Mexico — Despite good visual results, endothelial cell loss remains an issue following phakic IOL implantation, according to a surgeon speaking here.

Beatriz Martínez Blas, MD, and colleagues compared rates of endothelial cell loss between 48 eyes of 27 myopic patients implanted with the Artisan phakic IOL (Ophtec) and a control group of 44 non-implanted eyes of 25 myopic patients.

Dr. Martínez Blas presented the results at the Mexican Congress of Ophthalmology.

Preoperative myopia ranged from 9 D to 26 D in phakic IOL-implanted eyes and from 7 D to 26 D in control eyes.

The researchers found that mean endothelial cell counts in implanted eyes decreased 13% from 2551.04 at preop to 2222.2 at 12 months follow-up. In contrast, endothelial cell counts in control eyes decreased only 2% from 2561.61 at preop to 2504.36 at follow-up, Dr. Martínez Blas said.

"Implantation of the Artisan lens for the correction of myopia is one more alternative. However, the loss of corneal endothelial cells is evident. For this reason, continued monitoring is necessary in order to confirm the long-term impact," she said.

The Artisan phakic IOL is marketed in North America by Advanced Medical Optics under the brand name Verisyse.